Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Neuroscience
Lilly to acquire axon-loss-prevention start-up Disarm Therapeutics
by Ryan Cross
October 24, 2020
| A version of this story appeared in
Volume 98, Issue 41
Eli Lilly and Company will acquire the Cambridge, Massachusetts–based start-up Disarm Therapeutics for $135 million. Disarm is developing small-molecule inhibitors of SARM1. Two of the company’s cofounders, Jeffrey Milbrandt and Aaron DiAntonio of Washington University School of Medicine in St. Louis, discovered that the protein promotes the degeneration of the nervous system’s axons after injury. Blocking SARM1 could deter axon loss in neurological diseases such as amyotrophic lateral sclerosis and multiple sclerosis, Lilly says.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X